Breakdown | ||||
Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.30T | 1.26T | 1.24T | 1.16T | 1.06T | Gross Profit |
420.61B | 392.19B | 377.24B | 355.95B | 330.39B | EBIT |
107.95B | 94.40B | 91.67B | 88.88B | 67.30B | EBITDA |
174.77B | 165.25B | 150.80B | 137.58B | 116.65B | Net Income Common Stockholders |
81.92B | 77.93B | 69.26B | 37.07B | 41.54B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
142.59B | 138.57B | 101.08B | 144.53B | 87.45B | Total Assets |
1.33T | 1.32T | 1.23T | 1.20T | 1.15T | Total Debt |
110.83B | 120.72B | 120.46B | 122.56B | 138.17B | Net Debt |
-31.76B | -17.85B | 19.38B | -21.98B | 50.71B | Total Liabilities |
495.42B | 502.32B | 495.61B | 496.17B | 455.75B | Stockholders Equity |
807.35B | 792.33B | 705.03B | 674.64B | 667.07B |
Cash Flow | Free Cash Flow | |||
61.13B | 46.18B | 15.14B | 60.41B | 13.20B | Operating Cash Flow |
119.23B | 106.63B | 71.54B | 105.02B | 75.27B | Investing Cash Flow |
-61.51B | -18.52B | -59.43B | 2.69B | -58.49B | Financing Cash Flow |
-61.20B | -53.02B | -62.91B | -54.73B | -19.16B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $1.02T | 12.52 | 10.10% | 2.72% | 3.28% | 6.56% | |
66 Neutral | $4.47B | 12.22 | 5.40% | 3.65% | 4.14% | -12.00% | |
$2.35B | 10.94 | 15.22% | 2.20% | ― | ― | ||
$1.47B | 7.97 | -17.62% | 0.03% | ― | ― | ||
$22.15B | 9.27 | 14.04% | 0.02% | ― | ― | ||
$1.92B | 4.43 | 20.86% | 0.02% | ― | ― | ||
78 Outperform | ¥236.64B | 13.61 | 3.64% | 5.10% | 12.58% |
Sekisui Chemical Co., Ltd. has completed the acquisition of 4,000,000 of its own common shares at a total cost of 9,988,637,250 yen. This move, executed through market buying on the Tokyo Stock Exchange, aligns with the company’s strategic decision to manage its capital structure effectively, potentially enhancing shareholder value.
The most recent analyst rating on (JP:4204) stock is a Hold with a Yen2540.00 price target. To see the full list of analyst forecasts on Sekisui Chemical Co stock, see the JP:4204 Stock Forecast page.
Sekisui Chemical Co., Ltd. has announced the successful acquisition of 3,930,000 of its own common shares through the Tokyo Stock Exchange’s ToSTNeT-3 system, at a total cost of 9,813,210,000 yen. This move is part of the company’s strategy to maintain a flexible capital structure in response to changing business conditions, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (JP:4204) stock is a Hold with a Yen2540.00 price target. To see the full list of analyst forecasts on Sekisui Chemical Co stock, see the JP:4204 Stock Forecast page.
Sekisui Chemical Co., Ltd. has announced its decision to purchase up to 4,000,000 of its own common shares through the ToSTNeT-3 system of the Tokyo Stock Exchange at a set price of 2,497 yen per share. This strategic move, with a maximum acquisition cost of 9,988,000,000 yen, is part of a broader plan approved by the Board of Directors to enhance shareholder value and optimize capital structure, with the acquisition period extending until March 31, 2026.
The most recent analyst rating on (JP:4204) stock is a Hold with a Yen2540.00 price target. To see the full list of analyst forecasts on Sekisui Chemical Co stock, see the JP:4204 Stock Forecast page.
Sekisui Chemical Co., Ltd. has announced a decision to pay a fiscal year-end dividend of ¥42 per share, maintaining the amount forecasted earlier. This decision aligns with the company’s policy to ensure a dividend payout ratio of 40% or higher and reflects its commitment to shareholder returns. The total dividend for the fiscal year amounts to ¥79 per share, highlighting the company’s stable financial performance and strategic focus on rewarding shareholders.
The most recent analyst rating on (JP:4204) stock is a Hold with a Yen2540.00 price target. To see the full list of analyst forecasts on Sekisui Chemical Co stock, see the JP:4204 Stock Forecast page.
Sekisui Chemical Co., Ltd. has announced its decision to purchase and subsequently cancel up to 4,000,000 of its common shares. This move, aimed at improving capital efficiency and allowing for flexible capital policies, involves a maximum acquisition cost of 10.8 billion yen and is scheduled to occur between April 30, 2025, and March 31, 2026. The cancellation of these shares is set for May 23, 2025, which will reduce the total number of issued shares to 440,507,285. This strategic decision reflects Sekisui Chemical’s response to changing business environments and its commitment to optimizing shareholder value.
Sekisui Chemical Co., Ltd. announced a continuation and partial revision of its share-based compensation plan for directors and executive officers. The revision aims to align the interests of the company’s directors with shareholders by increasing the upper limit of funds for acquiring company shares, thereby enhancing the commitment to improving the group’s performance and corporate value over the medium to long term.
Sekisui Chemical Co., Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a decrease in comprehensive income by 55.4% compared to the previous year. The company has made changes in its scope of consolidation, including the addition of four companies and the exclusion of two, which may impact its future financial performance and market positioning.
Sekisui Chemical Co., Ltd. announced an upward revision to its dividend forecast for the fiscal year ending March 31, 2025, increasing the year-end dividend per share by 2 yen to 42 yen. This adjustment reflects the company’s commitment to enhancing shareholder value and aligns with its policy of maintaining a dividend payout ratio of 40% or higher, while also considering factors such as investment progress and cash position.